A novel triple adjuvant formulation promotes strong, Th1-biased immune responses and significant antigen retention at the site of injection

Vaccine

Volumn 28, Issue 52, 2010, Pages 8288-8299

  Wilson, Heather L ^a   Kovacs Nolan, Jennifer ^b   Latimer, Laura ^a   Buchanan, Rachelle ^a   Gomis, Susantha ^c   Babiuk, Lorne ^d   van Drunen Littel van den Hurk, Sylvia ^a,e  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF GUELPH   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adjuvants; Antigen retention; Fluorescent imaging; Polyphosphazenes

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; INDOLICIDIN; OVALBUMIN PLUS POLY(PDICARBOXYLATOPHENOXY) PHOSPHAZENE PLUS INDOLICIDIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNE RESPONSE; INJECTION SITE; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TISSUE REACTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; FEMALE; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; INTERLEUKIN-5; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; ORGANOPHOSPHORUS COMPOUNDS; OVALBUMIN; POLYMERS; TH1 CELLS; VACCINATION;

EID: 78649744699     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.006     Document Type: Article

References (53)

1. Schijns V.E. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 2000, 12(4):456-463.
2. Brown K.L., Hancock R.E. Cationic host defense (antimicrobial) peptides. Curr Opin Immunol 2006, 18(1 (February)):24-30.
3. Hancock R.E. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001, 1(3 (October)):156-164.
4. Oppenheim J.J., Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 2005, 17(4 (August)):359-365.
5. Murakami M., Dorschner R.A., Stern L.J., Lin K.H., Gallo R.L. Expression and secretion of cathelicidin antimicrobial peptides in murine mammary glands and human milk. Pediatr Res 2005, 57(1 (January)):10-15.
6. Murakami M., Ohtake T., Dorschner R.A., Gallo R.L. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res 2002, 81(12 (December)):845-850.
7. Murakami M., Ohtake T., Dorschner R.A., Schittek B., Garbe C., Gallo R.L. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 2002, 119(5 (November)):1090-1095.
8. Iimura M., Gallo R.L., Hase K., Miyamoto Y., Eckmann L., Kagnoff M.F. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J Immunol 2005, 174(8 (April 15)):4901-4907.
9. Phadke S.M., Deslouches B., Hileman S.E., Montelaro R.C., Wiesenfeld H.C., Mietzner T.A. Antimicrobial peptides in mucosal secretions: the importance of local secretions in mitigating infection. J Nutr 2005, 135(5 (May 1)):1289-1293.
10. Bowdish D.M., Davidson D.J., Scott M.G., Hancock R.E. Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 2005, 49(5 (May 15)):1727-1732.
11. Oppenheim J.J., Biragyn A., Kwak L.W., Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 2003, 62(90002 (November 1)):17ii-21ii.
12. Kovacs-Nolan J., Mapletoft J.W., Lawman Z., Babiuk L.A., van Drunen Littel-van den Hurk S. Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice. J Gen Virol 2009, 90(Pt 8):1892-1905.
13. Kovacs-Nolan J., Latimer L., Landi A., Jenssen H., Hancock R.E.W., Babiuk L.A., et al. The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. Vaccine 2009, 27(14):2055-2064.
14. Schellack C., Prinz K., Egyed A., Fritz J.H., Wittmann B., Ginzler M., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006, 24(26):5461-5472.
15. Bauer M., Heeg K., Wagner H., Lipford G.B. DNA activates human immune cells through a CpG sequence-dependent manner. Immunology 1999, 97(4 (August)):699-705.
16. Messina J.P., Gilkeson G.S., Pisetsky D.S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 1991, 147(6 (September 15)):1759-1764.
17. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374(6522 (April 6)):546-549.
18. Brown W.C., Estes D.M., Chantler S.E., Kegerreis K.A., Suarez C.E. DNA and a CpG oligonucleotide derived from Babesia bovis are mitogenic for bovine B cells. Infect Immun 1998, 66(11):5423-5432.
19. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408(6813 (December 7)):740-745.
20. Shoda L.K.M., Kegerreis K.A., Suarez C.E., Mwangi W., Knowles D.P., Brown W.C. Immunostimulatory CpG-modified plasmid DNA enhances IL-12, TNF-alpha, and NO production by bovine macrophages. J Leukoc Biol 2001, 70(1 (July 1)):103-112.
21. Sparwasser T., Miethke T., Lipford G., Erdmann A., Hacker H., Heeg K., et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol 1997, 27(7 (July)):1671-1679.
22. Stacey K.J., Sweet M.J., Hume D.A. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996, 157(5 (September 1)):2116-2122.
23. Krug A., Rothenfusser S., Hornung V., Jahrsdorfer B., Blackwell S., Ballas Z.K., et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001, 31(7 (July)):2154-2163.
24. Hartmann G., Krieg A.M. CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther 1999, 6(5 (May)):893-903.
25. Hartmann G., Weiner G.J., Krieg A.M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A 1999, 96(16 (August 3)):9305-9310.
26. Jakob T., Walker P.S., Krieg A.M., Udey M.C., Vogel J.C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998, 161(6 (September 15)):3042-3049.
27. Qiao B., Li B., Yang X., Zhang H., Chu Y., Wang Y., et al. Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation. Cell Mol Immunol 2005, 2(2 (April)):130-135.
28. Takeshita F., Klinman D.M. CpG ODN-mediated regulation of IL-12 p40 transcription. Eur J Immunol 2000, 30(7 (July)):1967-1976.
29. Cowdery J.S., Chace J.H., Yi A.K., Krieg A.M. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 1996, 156(12 (June 15)):4570-4575.
30. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997, 186(10 (November 17)):1623-1631.
31. Ioannou X.P., Griebel P., Hecker R., Babiuk L.A., van Drunen Littel-van den Hurk S. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol 2002, 76(18 (September)):9002-9010.
32. Klinman D.M., Conover J., Coban C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun 1999, 67(11 (November)):5658-5663.
33. Kovacs-Nolan J., Mapletoft J.W., Latimer L., Babiuk L.A. Hurk SvDL-vd. CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle. Vaccine 2009, 27(14):2048-2054.
34. Sur S., Wild J.S., Choudhury B.K., Sur N., Alam R., Klinman D.M. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999, 162(10 (May 15)):6284-6293.
35. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998, 160(2 (January 15)):870-876.
36. Weeratna R.D., Brazolot Millan C.L., McCluskie M.J., Davis H.L. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol 2001, 32(1 (December)):65-71.
37. Andrianov A.K., Chen J., Payne L.G. Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions. Biomaterials 1998, 19(1-3 (January-February)):109-115.
38. Mutwiri G., Benjamin P., Soita H., Townsend H., Yost R., Roberts B., et al. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 2007, 25(7):1204-1213.
39. Payne L.G., Jenkins S.A., Woods A.L., Grund E.M., Geribo W.E., Loebelenz J.R., et al. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 1998, 16(1 (January)):92-98.
40. McNeal M.M., Rae M.N., Ward R.L. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 1999, 17(11-12 (March 17)):1573-1580.
41. Wu J.Y., Wade W.F., Taylor R.K. Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect Immun 2001, 69(12 (December)):7695-7702.
42. Roberts T.L., Sweet M.J., Hume D.A., Stacey K.J. Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol 2005, 174(2 (January 15)):605-608.
43. Ioannou X.P., Gomis S.M., Karvonen B., Hecker R., Babiuk L.A., van Drunen Littel-van den Hurk S. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 2002, 21(1-2 (November 22)):127-137.
44. Mapletoft J.W., Oumouna M., Kovacs-Nolan J., Latimer L., Mutwiri G., Babiuk L.A., et al. Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J Gen Virol 2008, 89(Pt 1):250-260.
45. Finkelman F.D., Urban J.F. The other side of the coin: the protective role of the TH2 cytokines. J Allergy Clin Immunol 2001, 107(5):772-780.
46. Mutwiri G., Benjamin P., Soita H., Babiuk L.A. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine 2008, 26(22):2680-2688.
47. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004, 10(2 (February)):187-192.
48. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6(5):723-739.
49. Haeryfar S.M.M., DiPaolo R.J., Tscharke D.C., Bennink J.R., Yewdell J.W., Regulatory T cells suppress CD8+T cell responses induced by direct priming and cross-priming and moderate immunodominance disparities. J Immunol 2005, 174(6 (March 15)):3344-3351.
50. Faries M.B., Hsueh E.C., Ye X., Hoban M., Morton D.L. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res 2009, 15(22):7029-7035.
51. Kumar S., Jones T.R., Oakley M.S., Zheng H., Kuppusamy S.P., Taye A., et al. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun 2004, 72(2):949-957.
52. Ellis R.D., Martin L.B., Shaffer D., Long C.A., Miura K., Fay M.P., et al. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/alhydrogel with and without CPG 7909 in malaria naive adults. PLoS One 2010, 5(1):e8787.
53. Zhu Q., Egelston C., Gagnon S., Sui Y., Belyakov I.M., Klinman D.M., et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 2010, 120(2):607-616.